Connect with us

Market

Notable Movers: AMC Networks (NASDAQ:AMCX), Aldeyra Therapeutics (ALDX)

Published

on

Thinly traded micro cap Aldeyra Therapeutics (ALDX) is down 4% on below-average volume following its pipeline update at its R&D Day. Highlights:

Reproxalap: A two-part Phase 3 trial should start in H1. The first part will confirm dosing and size for the second part.

Topline data from the Phase 3 ALLEVIATE study in allergic conjunctivitis (AC) should be available this quarter (the study was completed in November 2018 so investors appear anxious to see the data).

Parallel studies in overlapping treatment of dry eye disease and AC are planned to support U.S. marketing applications.

Topline data from the Phase 3 SOLACE study in non-infectious anterior uveitis should be available in H2.

ADX-2191: A Phase 3 study in proliferative vitreoretinopathy, a rare complication of retinal detachment, should launch in H2 (Orphan Drug indication in the U.S.).

Wow the future of Autonomous flight is finally here with the launch of ASDN passenger drone Elroy

AMC Networks (NASDAQ:AMCX) has risen 5.5% this morning after outperforming with its Q4 results, growing profits with strong international revenues and seeing late strength from its flagship drama.

Adjusted operating income rose 6.6% to $219M on revenues that grew 6.3%.

Net income was $72M, down from a year-ago $145M that benefited from a tax-reform impact of $57M. This quarter also featured a $43M restructuring expense.

For the full year, AMC aired three of the top six dramas on ad-supported cable, with The Walking Dead holding on at No. 1; prequel series Fear the Walking Dead at No. 4; and Better Call Saul at No. 6.

Revenue by segment: National Networks, $592.7M (down 2.2%); International and other, $188.4M (up 48.6%)

Operating income (GAAP basis) by segment: National Networks, $177.8M (up 0.6%); International and other, -$48.4M (down from -$19.7M).

Why Investors Are Calling ASDN the TPC of the Sky!

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

Rockwell Medical Inc (NASDAQ: RMTI): Premium Members Made A Quick 20% Profit In 24 Hours

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Rockwell Medical Inc (NASDAQ: RMTI) yesterday (march 18th) at $5.42. Now look at the price of the stock – its up 20% at $6.55 from our buy price. This is how easy money they made. If you had invested $5,000 in RMTI, it could had been moved up to $6,000. It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

Sorrento Therapeutics Inc (NASDAQ: SRNE): Members Made A Hefty 15% Profit In 24 Hours

Published

on

By

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/

 JOIN US NOW: For Details Contact us at info@tradersinsights.com

 Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Sorrento Therapeutics Inc (NASDAQ: SRNE) yesterday (march 18th) at $2.67. Now look at the price of the stock – its up 15% at $3.23 from our buy price. This is how easy money they made. If you had invested $5,000 in SRNE, it could had been moved up to $5,750.  It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending